Seagen - SGEN Stock Forecast, Price & News

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings or view top-rated stocks.

17 equities research analysts have issued twelve-month price targets for Seagen's stock. Their SGEN share price forecasts range from $129.00 to $229.00. On average, they expect the company's share price to reach $188.33 in the next twelve months. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for SGEN or view top-rated stocks among Wall Street analysts.

Seagen's stock was trading at $128.51 at the beginning of the year. Since then, SGEN shares have increased by 57.4% and is now trading at $202.23.
View the best growth stocks for 2023 here.

Seagen saw a decline in short interest in March. As of March 15th, there was short interest totaling 1,820,000 shares, a decline of 44.7% from the February 28th total of 3,290,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 1.4 days.
View Seagen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our SGEN earnings forecast.

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings results on Wednesday, February, 15th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.22. The biotechnology company had revenue of $528.20 million for the quarter, compared to analysts' expectations of $479.81 million. Seagen had a negative net margin of 31.10% and a negative trailing twelve-month return on equity of 21.13%. The business's revenue was up 22.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) EPS.

ETFs with the largest weight of Seagen (NASDAQ:SGEN) stock in their portfolio include Principal Healthcare Innovators ETF (BTEC), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Vesper U.S. Large Cap Short-Term Reversal Strategy ETF (UTRN), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ), Goldman Sachs Future Health Care Equity ETF (GDOC) and Virtus LifeSci Biotech Products ETF (BBP).

Seagen updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.14 billion-$2.24 billion, compared to the consensus revenue estimate of $2.30 billion.

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.76%), Norges Bank (1.18%), Geode Capital Management LLC (1.03%), Avoro Capital Advisors LLC (1.02%), Franklin Resources Inc. (0.94%) and T. Rowe Price Investment Management Inc. (0.87%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, Daniel G Welch, David W Gryska, David W Gryska, Jean I Liu, Jean I Liu, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends.

Shares of SGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $202.23.

Seagen (NASDAQ:SGEN) has a market capitalization of $37.77 billion and generates $1.96 billion in revenue each year. The biotechnology company earns $-610,310,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis.

The company employs 3,256 workers across the globe.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The official website for the company is www.seattlegenetics.com. The biotechnology company can be reached via phone at (425) 527-4000, via email at investors@seagen.com, or via fax at 425-527-4001.